the present invention is based upon the discovery and isolation of a highly inducible 30 kda protein that is released by , and accumulates in media conditioned by , cultured murine macrophage - like cells ( raw 264 . 7 ) following stimulation with lps , tnf , or il - 1 . a partial amino acid sequence of this isolated polypeptide was identical to the sequence of the hmg1 protein , also known as amphoterin , a protein not before linked to the pathogenesis of any disease . this information was used to clone a cdna encoding hmg1 , which sequence was expressed to provide recombinant protein , which protein was used to generate specific anti - hmg1 antibodies . therapeutic and diagnostic efficacy was determined in a series of predictive in vitro and in vivo experiments . the experiments are detailed in the examples section . for example , following administration of endotoxin ( ld 100 ) to mice , serum hmg1 levels increased later ( at 16 h ) than well - known “ early ” mediators of sepsis ( such as tnf and il - 1 ) and plateau levels of ilmgi were maintained for 16 to 32 hours . patients with lethal sepsis had high serum hmg1 levels , which were not detected in normal healthy volunteers . moreover , acute experimental administration of rhmg1 to test animals , whether alone or in combination with sub - lethal amounts of lps , caused marked pathological responses and even death . more distributed dosing schedules of lower amounts of rhmg1 led to significant weight loss in treated animals . these results give evidence that hmg1 is a mediator of endotoxemia and particularly a late mediator , as opposed to known “ early ” mediators such as tnf and il - 1 . these data further show the importance of serum hmg1 as a marker for the severity or potential lethality of sepsis and related conditions . in addition , treatment with anti - hmg1 antibodies provided full protection from ld 100 doses of lps in mice . hmg1 is inducible by tnf and il - 1β , and dose - dependently stimulates tnt release from hupbmcs . tnf is a marker of macrophage activation , so it is likely ( without limitation as to implied mechanisms or being bound by theory ) that hmg1 promotes downstream re - activation of cytokine cascades which , in turn , mediates late pathogenesis and lethality in sepsis and related conditions involving activation of pro - inflammatory cytokine responses . thus , hmg1 likely occupies a central role in mediating the inflammatory response to infection and injury , and antagonists of hmg1 will be of therapeutic benefit in sepsis and related conditions of inflammatory cascade activation . the appearance of hmg1 in the inflammatory cytokine cascade is suitable to propagate later phases of the host response and contribute to toxicity and lethality . the predictive data provided herein support the therapeutic efficacy of hmg1 antagonists and provide evidence in support of the aforementioned theory regarding mechanism of action . the in vivo treatment data showed the efficacy of hmg1 antagonists in general and anti - hmg1 antibodies in particular , for treating conditions mediated by the inflammatory cytokine cascade in general and particularly sepsis conditions , including , for example , septic shock , sepsis syndrome or other “ sepsis - like ” conditions mediated by inflammatory cytokines . further , the independent pathogenicity and toxicity / lethality of hmg1 shows that hmg1 antagonists are particularly effective when co - administered with antagonists of “ early ” inflammatory mediators such as tnf , mif , il - 1 and il - 6 . in summary , hmg1 is a cytokine mediator of inflammatory reactions because : 1 ) hmg1 is released from macrophages and pituicytes following stimulation with bacterial toxins or with pro - inflammatory cytokines ( tnf or il - 1β ); 2 ) hmg1 accumulates in serum of animals exposed to lps and in patients with sepsis ; and 3 ) hmg1 - specific antibodies protect against mortality in a predictive lethal endotoxemia animal model of clinical sepsis and related conditions . the inventive pharmaceutical composition or inventive pharmaceutical combination can be administered to a patient either by itself ( complex or combination ) or in pharmaceutical compositions where it is mixed with suitable carriers and excipients . the inventive pharmaceutical composition or inventive pharmaceutical combination can be administered parenterally , such as by intravenous injection or infusion , intraperitoneal injection , subcutaneous injection , or intramuscular injection . the inventive pharmaceutical composition or inventive pharmaceutical combination can be administered orally or rectally through appropriate formulation with carriers and excipients to form tablets , pills , capsules , liquids , gels , syrups , slurries , suspensions and the like . the inventive pharmaceutical composition or inventive pharmaceutical combination can be administered topically , such as by skin patch , to achieve consistent systemic levels of active agent . the inventive pharmaceutical composition or inventive pharmaceutical combination can be formulated into topical creams , skin or mucosal patches , liquids or gels suitable for topical application to skin or mucosal membrane surfaces . the inventive pharmaceutical composition or inventive pharmaceutical combination can be administered by inhaler to the respiratory tract for local or systemic treatment . the dosage of the inventive pharmaceutical composition or inventive pharmaceutical combination of the present invention can be determined by those skilled in the art from this disclosure . the pharmaceutical composition or inventive pharmaceutical combination will contain an effective dosage ( depending upon the route of administration and pharmacokinetics of the active agent ) of the inventive pharmaceutical composition or inventive pharmaceutical combination and suitable pharmaceutical carriers and excipients , which are suitable for the particular route of administration of the formulation ( i . e ., oral , parenteral , topical or by inhalation ). the active agent is mixed into the pharmaceutical formulation by means of mixing , dissolving , granulating , dragee - making , emulsifying , encapsulating , entrapping or lyophilizing processes . the pharmaceutical formulations for parenteral administration include aqueous solutions of the active agent or combination in water - soluble form . additionally , suspensions of the active agent may be prepared as oily injection suspensions . suitable lipophilic solvents or vehicles include fatty oils such as sesame oil , or synthetic fatty acid esters , such as ethyl oleate or triglycerides , or liposomes . aqueous injection suspensions may contain substances which increase the viscosity of the suspension , such as sodium carboxymethyl cellulose , sorbitol , or dextran . the suspension may optionally contain stabilizers or agents to increase the solubility of the active agent or combination to allow for more concentrated solutions . pharmaceutical formulations for oral administration can be obtained by combining the active agent with solid excipients , such as sugars ( e . g ., lactose , sucrose , mannitol or sorbitol ), cellulose preparations ( e . g ., starch , methyl cellulose , hydroxypropylmethyl cellulose , and sodium carboxymethyl cellulose ), gelaten , gums , or polyvinylpyrrolidone . in addition , a disintegrating agent may be added , and a stabilizer may be added . the present invention provides antisense oligomers having a sequence effective to inhibit or block the expression of the hmg1 gene or mrna sequence . antisense technology , which uses specific - oligonucleotides to inhibit expression of target gene products , is developing as a therapeutic modality for human disease . several selection criteria are available to contribute to the optimization of antisense oligonucleotide antagonists . for example , it is advisable to choose sequences with 50 % or more gc content . preferred sequences span the aug initiation codon of the target protein , but sites in the coding region and 5 ′ utr may perform equally well . such sequences are generally about 18 - 30 nucleotides long and chosen to overlap the atg initiation codon from the hmg1 cdna sequence to inhibit protein expression . longer oligomers are often found to inhibit the target to a greater extent , indicating that a preferred length is about 25 mer for the first oligonucleotides chosen as antisense reagents . typically , three oligonucleotide sequences are chosen with regard to these criteria , and compared for antagonist activity to control oligonucleotide sequences , such as “ reverse ” oligonucleotides or those in which about every fourth base of the antisense sequence is randomized . therefore , a preferred sequence for making antisense oligomer sequences to hmg1 is a 25 mer sequence chosen to overlap the atg initiation codon ( underlined ) from the hmg1 cdna sequence : and such preferred antisense sequences are used to construct antisense oligonucleotide agents ( and suitable controls ) for an in vitro comparison as antagonists of hmg1 . these in vitro data are predictive of human clinical utility using antisense agents of comparable design . the antibodies disclosed herein may be polyclonal or monoclolnal ; may be from any of a number of human , non - human eukaryotic , cellular , fungal or bacterial sources ; may be encoded by genomic or vector - borne coding sequences ; and may be elicited against native or recombinant hmg1 or fragments thereof with or without the use of adjuvants , all according to a variety of methods and procedures well - known in the art for generating and producing antibodies . generally , neutralizing antibodies against hmg1 ( i . e ., those that inhibit biological activities of hmg1 particularly with regard to its pro - inflammatory cytokine - like role ) are preferred for therapeutic applications while non - neutralizing antibodies may be as suitable for diagnostic applications . examples of such useful antibodies include but are not limited to polyclonal , monoclonal , chimeric , single - chain , and various human or humanized types of antibodies , as well as various fragments thereof such as fab fragments and fragments produced from specialized expression systems . the diagnostic assay provided here uses anti - hmg1 antibodies that can be either polycolonal or monoclonal or both . the diagnostic procedure can utilize standard antibody - based techniques for measuring concentrations of the gene product of hmg1 genes in a biological fluid . preferred standard diagnostic procedures are elisa assays and western techniques . this example provides the results of an experiment to identify and isolate later released macrophage - derived factors that play a role in sepsis and in related conditions typified by inflammatory cytokine activity . the experiment reported in this example examined murine macrophage raw 264 . 7 cell - conditioned media after stimulation of the cultures with tnf . murine macrophage raw 264 . 7 cells were obtained from american type culture collections ( atcc , rockville , md ., usa ), and proliferated in culture under dmem ; supplemented with 10 % fetal bovine serum and 1 % glutamine . when confluency reached 70 - 80 %, the medium was replaced by serum - free opti - mem i medium and cultures were stimulated with pro - inflammatory cytokines ( e . g ., tnfα or il - 1 ) or bacterial endotoxin ( lps ). the proteins released from the above stimulated macrophage cultures were surveyed . specifically , at different time points , cells and cell - conditioned media were separately collected by centrifugation ( 3000 rpm , 10 minutes ). proteins in the conditioned mediam were concentrated by ultrafiltration over amicon membranes with mr cutoff of 10 kda ( amicon inc ., beverly , mass ., usa ), subsequently fractionated by sds - page , and stained with coomassie blue ( 1 . 25 % coomassie blue r250 in 30 % methanol / 10 % acetic acid ). after destaining with 30 % methanol / 7 % acetic acid , protein ( s ) of interest ( i . e ., those that preferentially accumulated in conditioned media of stimulated cultures ) was isolated by excision from the sds - page gel , and subjected to n - terminal sequencing analysis ( commonwealth biotechnologies , inc ., richmond , va ., usa ). comparison of sds - page gel analysis of profiles of proteins accumulated in control ( without tnfα stimulation ) versus tnf - stimulated raw 264 . 7 cells revealed a strongly inducible 30 kda protein whose concentration in the cell - conditioned medium was significantly increased after stimulation for 16 hours . amino acid sequence analysis of this isolated protein revealed its n - terminal sequence as gly - lys - gly - asp - pro - lys - lys - pro - arg - gly - lys - met - ser - ser [ seq id no . 1 ]. a review of relevant gene databases found a 100 % identity to the n - terminal amino acid sequence of hmg1 . these data identified hmg1 as a “ late - appearing ” product of lps - stimulated macrophage cultures , and therefore as a candidate pro - inflammatory mediator . this activity was confirmed by administration of recombinantly produced hmg1 and / or of anti - hmg1 antibodies in cellular and animal model systems that are predictive of human clinical conditions . this example shows which cell sources are capable of releasing hmg1 in response to tnf , il - 1 and / or lps . cells studied include gh 3 pituicytes , murine macrophage raw 264 . 7 cells , human primary peripheral blood mononuclear cells ( hupbmcs ), human primary t cells , rat adrenal pc - 12 cells , and rat primary kidney cells ( table 1 ). the rat pituitary gh 3 cell line was obtained from american type culture collection ( atcc , rockville , md ., usa ), and cultured in deme supplemented with 10 % fetal bovine serum and 1 % glutamine . human pbmcs and t cells were freshly isolated from whole blood of healthy donors and cultured in rpmi 1640 supplemented with 10 % human serum as previously described ( zhang et , al ., j . exp . med . 185 : 1759 - 1768 , 1997 ). when confluency reached 70 - 80 %, the medium was replaced by serum - free opti - mem i medium and cultures stimulated with proinflammatory ; cytokines ( e . g ., tnfα or il - 1 ) or bacterial endotoxin ( lps ). although human t cell , rat adrenal ( pc - 12 ) cells , and rat primary kidney cells contained cell - associated hmg1 as demonstrated by western blotting analysis of whole cell lysates using hmg1 - specific antibodies ( see example 4 below ), hmg1 did not significantly accumulate in the medium of these cultures after stimulation with either tnf , il - 1β , or lps ( table 1 ). tnf , il - 1β ( minimal effective concentration = 5 ng / ml for each ) and bacterial endotoxin ( lps , minimal effective concentration = 10 ng / ml ) induced the release of hm , gi from human pbmcs in a time - and dose - dependent manner ( table 1 ). ifn - γ alone ( 0 - 200 u / ml ) did not induce hmg1 release from any of the above cells , but when added in combination either with tnf or il - 1β , ifn - γ dose - dependently enhanced hmg1 release from macrophages , with a maximal 3 - fold enhancement by ifn - γ at a concentration of 100 u / ml . the release of hmg1 was not due to cell death , because cell viability was unaffected by tnf , il - 1 β , or lps , as judged by trypan blue exclusion ( 90 - 92 ± 5 % viable for control vs . 88 - 95 ± 4 % in the presence of 100 ng / ml , tnf , il - 1β or lps ). the amount of hmg1 released by pituicytes and macrophages inversely correlated with the intracellular concentration of hmg1 , as determined by western blotting analysis , indicating that the released material is , in part , derived from pre - formed cell - associated hmg1 protein . potential sources of circulating hmg1 in vivo were assessed by hybridization of an hmg1 - specific probe to mkrna prepared from various normal human tissues ( blot substrate available from commercial sources ), with the results summarized in fig5 . several macrophage - rich tissues ( lung , liver , kidney , pancreas and spleen ) exhibited the most abundant hmg1 mrna expression ; less was observed in pituitary , bone marrow , thymus , lymph node and adrenal gland . in addition to providing information as to the relative tissue distribution of hmg1 expression , this study shows the practicality and utility of assaying for hmg1 - specific nucleic acid sequences in tissue samples . this example details procedures to produce hmg1 by well - known recombinant dna technologies . the hmg1 open reading frame was amplified by pcr and subcloned into an expression vector ( pcal - n ). briefly , the 648 - bp open reading frame of hmg1 cdna was pcr amplified ( 94 ° c . 1 ′, 56 ° c . 2 ′, 72 ° c . 45 ″, 30 cycles ) from 5 ng rat brain quick - clone cdna ( catalog # 7150 - 1 , clontech , palo alto , calif ., usa ) using primers containing the following sequences , 5 ′- ccc gcg gat cca tcg agg gaa gga tgg gca aag gag atc cta - 3 ′[ seq id no . 2 ], and 5 ′- ccc gca agc tta ttc atc atc atc atc ttc t - 3 ′ [ seq id no . 3 ]. the 680 bp pcr product ( 4 μg ) was digested with bam hi and hind iii , and cloned into the bam hi / hind iii cloning sites of the pcal - n vector ( stratagene , la jolla , calif ., usa ). the recombinant plasmid was transformed into e . coli bl21 ( de3 ) plyss ( novagen , madison , wis ., usa ), and positive clones were screened and confirmed by dna sequencing on both strands using a tag dyedeoxy terminator cycle sequencing kit on the abi 373a automated fluorescent sequencer ( applied biosystems , foster city , calif ., usa ). to express recombinant hmg1 , positive clones were cultured at 37 ° c . with vigorous shaking ( 250 rpm ) until od 600 , reached 0 . 6 , when iptg ( 1 mm ) was added . twelve hours after iptg induction , bacterial cells were harvested by centrifugation ( 6500 rpm , 15 minutes ), and lysed by freeze - thaw cycles . the water - soluble fraction was collected after centrifugation ( 30 minutes , 12 , 000 rpm ), and recombinant hmg1 was purified on a calmodulin - binding resin column as instructed by the manufacturer ( stratagene ). bacterial endotoxin was removed from the recombinant hmg1 by using detoxi - gel endotoxin - removing gel ( pierce , rockford , ill . usa , cat . # 20344 ), and residual lps content was determined by the limulus amebocyte lysate test ( lal test , cat . # 50 - 648u , qcl - 1000 chromogenic lal , bio - whittaker , inc ., walkersville , md ., usa ). purified recombinant hmg1 was added to cultures of human peripheral blood mononuclear cells ( hupbmcs ), and supernatants assayed for tnf by elisa four hours after stimulation . the lps - neutralizing agent polymyxin b ( 10 μg / ml ) was added concurrently with recombinant hmg1 to eliminate the effect of any contaminating lps on tnf release . additionally , recombinantly derived hmg1 was administered to test animals , with or without the additional endotoxemic challenge of exogenous lps , to study the pathogenic potential of high levels of hmg1 in vivo ( see fig2 b and 2 c ). in some experiments , serum samples were secured from hmg1 - treated animals to be assayed for tnf as detailed herein ( see fig1 b ). the above procedure provides recombinant hmg1 as a fusion peptide comprising a 3 . 0 kda calmodulin - binding domain and a thrombin cleavage site as an amino terminal extension in register with the hmg1 peptide sequence . in some experiments , the fusion tag was removed from an aliquot of the recombinant protein and the bioactivity of the full fusion protein was compared to the cleaved hmg1 peptide ; no significant difference in bioactivity was noted and additional experiments ( especially those requiring administration of recombinantly produced hmg1 to animals ) typically were conducted with the ( uncleaved ) fusion protein . as demonstrated in fig3 a and 3b , in vitro or in vivo administration of recombinantly derived hmg1 induced a brisk tnf response , confirming the identification of hmg1 as a late - appearing lps - induced macrophage - derived endogenous mediator with pro - inflammatory activity . this example provides the results of experiments to generate and use polyclonal antibodies against hmg1 . briefly , polyclonal antibodies against an oligopeptide corresponding to the n - terminal amino acid sequence of hmg1 , or against purified recombinant hmg1 , were generated in rabbits according to standard procedures well known in the art . briefly , eight copies of an oligopeptide with the sequence gkgdpkkprgkmssc [ seq id no . 4 ] were anchored to radially branching lysine dendrites ( small immunogenically inert core ). these large macromolecules were injected three times both subcutaneously and intradermally ( 0 . 5 - 1 . 0 mg per injection ) into rabbits at week 1 , 2 , and 4 after pre - bleed at day 0 . two weeks after the last immunization , rabbits were bled and boosted intramuscularly with 1 . 0 mg of antigen , followed by a second bleeding two weeks later . alternatively , to produce polyclonal antibodies against recombinant hmg1 , rabbits were immunized with recombinant hmg1 fusion peptide ( 100 μg per injection ) following a similar protocol . monoclonal antibodies reactive against hmg1 ( i . e ., that bind , and in some cases , neutralize or antagonize the biological activity of hmg1 ) are conveniently prepared according to methods well known in the art using the hmg1 antigens described herein or other hmg1 peptide fragments as immunogens . such monoclonal antibodies , and / or the hybridomas that produce them , are useful to produce various “ humanized ” antibodies reactive against hmg1 ( all according to methods known in the art ), which humanized antibodies are useful as taught herein . hmg1 - specific antibodies were used to measure by western blotting analysis the inducible release of hmg1 from raw 264 . 7 cells after treatment with tnf or lps ( fig1 ). briefly , proteins were fractionated by sds - page on a 4 - 20 % gradient gel , transferred to a pvdf membrane , and blotted with rabbit antiserum raised against either the n - terminal synthetic hmg1 antigen or against recombinant hmg1 . the signal was detected using a ecl kit as instructed by the manufacturer ( amersham life science inc ., arlington heights , ill ., usa ), and levels of hmg1 were determined by measuring optical intensity of bands on western blots digitized for analysis using nih 1 . 59 image software , with reference to a standard curve of purified recombinant hmg1 . no hmg1 protein was detected in raw 264 . 7 cells - conditioned medium in the absence of inf or lps treatment , but hmg1 accumulated in conditioned medium to high levels after such stimulation , reaching a plateau at 8 - 28 hours after stimulation ( fig1 a ). in summary , the data presented in examples 1 , 3 and in fig1 a show that the release of hmg1 from macrophages is stimulus - specific and time - and dose - dependent , with maximal accumulation observed within 8 hours after stimulation with tnf at concentrations as low as 5 ng / ml . it is well appreciated that sepsis , septic shock and related conditions may occur in humans in response to stimuli that differ qualitatively or quantitatively from the single large , lethal lps bolus used in this predictive model . nevertheless , experimental endotoxemia has been a valuable and predictive model system by which to identify critical components of the inflammatory cytokine cascade and by which to identify specific antagonists with predicted clinical utility . in this regard , hmg1 antagonists are perhaps more therapeutically attractive than tnf antagonists in view of the later appearance of hmg1 versus tnf in the response to endotoxin . this example illustrates an in vivo experiment in rodents measuring serum hmg1 levels after administration of a sublethal dose of lps ( ld 50 ). mice or rats were treated with lps , and sera were collected at different time points , and assayed for levels of hmg1 by western blotting analysis . the serum concentrations of hmg1 were estimated by measuring the optical band intensity with reference to a standard curve of purified hmg1 . serum levels increased significantly by 16 hours after lps , and remained high for at least 32 hours ( fig1 b ), and were not detectable in vehicle - treated control animals . these data show that hmg1 represents a particularly attractive target for diagnosis of , and pharmaceutical intervention against , sepsis and related disorders of cytokine toxicity because hmg1 is a late - appearing mediator in the inflammatory cytokine cascade . this example provides the results of a predictive in vivo assay to measure therapeutic activity of antagonists of hmg1 in relation to treatment of sepsis and related conditions of cytokine - mediated toxicity . in this example , the hmg1 antagonist was an anti - hmg1 antibody preparation . controls treated with pre - immune serum developed lethargy , piloerection , diarrhea , and succumbed to death within 48 hours . these clinical signs of endotoxemia were significantly prevented by administration of anti - hmg1 antibodies . male balb / c mice ( 6 - 7 weeks , 20 - 23 grams ) were randomly grouped ( 10 animals per group ) and pre - treated either with control ( pre - immune ) or anti - hmg1 serum ( as made in example 4 ) 30 minutes before administration ( intraperitoneally ) of a lethal dose of lps ( 50 mg / kg in 1 × pbs ). other experimental groups received additional doses of anti - hmg1 serum at + 12 or , + 12 , and + 36 hours after lps administration . animals were observed for appearance and survival for at least two weeks . polyclonal antibodies against recombinant hmg1 were generated in rabbits , and antiserum was assayed for specificity and titer by elisa and western blotting procedures . the polyclonal antiserum immunospecifically recognized ( bound to ) recombinant hmg1 in western blot analysis , for instance , and discriminated rhmg1 from other proteins in both crude bacterial lysates and as a purified protein that had been diluted into mouse serum . using chemiluminescence - amplified detection methods in western blotting analysis , polyclonal anti - hmg1 antiserum at dilutions up to 1 : 1000 was useful to detect as little as 50 pg rhmg1 protein . administration of anti - hmg1 antiserum in the indicated ( fig2 a ) amounts at − 0 . 5 ( if one dose ), − 0 . 5 and 12 ( if two doses ), or − 0 . 5 , 12 and 36 ( if three doses ) hours relative to lps challenge ( at time 0 ) was protective against lps - induced lethality , and repeated dosing schedules provided better protection . fig2 b illustrates that rhmg1 causes dose - dependent lethality in endotoxic mice . male balb / c mice ( 20 - 23 grams ) were randomized in groups of ten to receive lps ( 3 . 15 mg / kg ; a non - lethal dose ) alone or in combination with purified recombinant hmg1 protein . administration of hmg1 at the indicated doses 2 , 16 , 28 and 40 hours after lps challenge significantly increased the lethality of the underlying endotoxemia . fig2 c illustrates the independent lethal toxicity of hmg1 as a function of dose . purified rhmg1 was administered to male balb / c mice ( five mice per treatment group ) as a single i . p . bolus at the indicated dosage . mice were observed for at least 48 hours , and 60 % of mice treated with rhmg1 at a dose of 500 μg / mouse died within 24 hours of rhmg1 challenge , indicating a single dose ld 50 of less than 500 μg / mouse . the protection conferred by anti - hmg1 antibodies was specific , because administration of pre - immune serum , which showed no immunospecific reactivity to hmg1 on western blots , did not spare subjects from lps - mediated mortality ( fig2 a ). moreover , hmg1 - specific antibodies did not cross - react with other macrophage - derived cytokines ( e g . il - 1 and tnf ), eliminating the possibility that antibodies conferred protection by binding and thereby neutralizing these mediators . protection against sepsis , sepsis associated pathogenesis and sepsis - related diseases involving activation of pro - inflammatory cytokine cascades may be improved by combination therapy targeted against more than one component of the cytokine cascade . antagonists of hmg1 in this regard can be combined with specific antagonists of tnf , il - 1 , mif and other inflammatory mediators , or with more broadly active antagonists of inflammatory responses that inhibit multiple components of the inflammatory cascade ( e . g ., aspirin , nsaids , anti - inflammatory steroids , etc . ), to provide even more effective therapeutics , modalities . protection against lps toxicity was antibody dose - related , and more frequent dosing with higher amounts of antibody reduced mortality by up to 70 % ( fig2 a ). mice were observed for at least 2 weeks in all experiments , and no late mortality occurred , indicating that anti - hmg1 antibody treatment confers lasting protection against lps lethality , and does not merely delay the time of death . this example provides data that establish an association between hmg1 and human sepsis , by support an indication for using hmg1 antagonists generally and anti - hmg1 in particular in human sepsis and related conditions of cytokine toxicity . serum hmg1 normal healthy individuals and critically ill patients were measured using the polyclonal generated as in example 4 in a western blot format with reference to a standard curve of rhmg1 . hmg1 was not detectable in normal controls , but accumulated to high levels in critically ill patients with sepsis ( table 2 ). these data show that elevated serum hmg1 levels are observed in patients with sepsis , and the highest levels of serum hmg1 are observed in lethal cases ( table : 2 ). these data further indicate the therapeutic importance of hmg1 antagonists in sepsis and also provide evidence for the diagnostic utility of an assay for sepsis and severity ( i . e ., potential lethality ) of sepsis by measuring serum concentrations of hmg1 . this diagnostic assay is also useful for diagnosing the severity of allied conditions involving activation of the inflammatory cytokine cascade . additional subjects were screened for serum hmg1 levels in association with lethal versus non - lethal sepsis , with results ( cumulative with table 2 ) as described in fig6 . the data summarized in fig6 represent serum samples obtained from eight healthy subjects and twenty - five septic patients infected with gram positive [ bacillus fragilis ( 1 patient ), enterococcus facecalis ( 1 patient ), streptococcus pneumonia ( 4 patients ), listeria monocytogenes ( 1 patient ), or staphylococcus aureus ( 2 patients )], gram negative [ escherichia coli ( 7 patients ), klebsiella pneumonia ( 1 patient ), acinetobacter calcoaceticus ( 1 patient ), pseudomonas aeruginosa ( 1 patient ), fusobacterium nucleatum ( 1 patient ), citrobacter freundii ( 1 patient )], or unidentified pathogens ( 5 patients ). serum was fractionated by sds - page gel electrophoresis , and hmg1 levels were determined by western blotting analysis with reference to standard curves of purified rhmg1 diluted in normal human serum . the detection limit by western blotting analysis is 50 pg . note that hmg1 is not detectable in normal controls , but significantly increased in septic patients . the average level of hmg1 in serum of non - surviving septic patients ( n = 13 patients , mean hmg1 level = 83 . 7 ± 22 . 3 ng / ml ) is significantly higher than in survivors ( n = 12 , mean hmg1 level = 25 . 2 ± 15 . 1 ng / ml , p & lt ; 0 . 05 ). these data provide direct evidence of the utility of screening tissue ( including , without limitation blood or serum ) samples for hmg1 sequences ( protein or nucleic acid ) as a diagnostic and prognostic indicator of the presence of sepsis and related disorders of cytokine activation and of the severity and likely clinical course of such diseases and conditions . the present results provide evidence that hmg1 is a late released mediator element of the inflammatory cytokine cascade . addition of recombinant hmg1 to primary human peripheral blood mononuclear cells led to the dose - dependent induction of tnf within four hours after stimulation ( fig3 a ). this stimulation by recombinant hmg1 of tnf release by hupbmcs was not due to lps contamination because : ( i ) purified recombinant hmg1 was not contaminated by lps as judged by an lal endotoxin assay ; ii ) addition of the lps - neutralizing agent polymyxin b did not affect hmg1 - induced tnf release ; and iii ) proteolytic cleavage of recombinant hmg1 preparations with trypsin completely abolished the tnf release activity for the pbmc cultures . hmg1 stimulation also induced macrophages to release nitric oxide ( no ). to confirm that hmg1 induced serum tnf release in vivo , purified recombinant hmg1 was administered intraperitoneally to balb / c mice , and blood samples were collected to be assayed for tnf by the l929 assay . as shown in fig3 b , tnf was not detectable in serum of control animals , but was significantly increased two hours after administration of recombinant hmg1 protein . repetitive administration of recombinant gene product of the hmg1 gene ( 100 μg / mouse / day ) caused significant body weight loss ( fig4 ) in mice . without limitation as to mechanism and without being bound by theory , these data are consistent with the hypothesis that hmg1 acts as a feed - forward stimulator of the pro - inflammatory cascade under both in vitro and in vivo conditions . these in vivo data in a predictive model of weight loss also provide predictive evidence that a pharmaceutical formulation comprising hmg1 , or a therapeutically active fragment thereof , is an effective weight loss therapy . serum hmg1 levels in hypophysectomized versus control rats also were measured by quantitation of western blot intensities as described above . there were significantly higher hmg1 levels within 12 hours after endotoxic challenge ( lps at 1 . 0 mg / kg ) in hypophysectomized rats ( approx . 75 ng / ml ) as compared to controls ( approx . 25 ng / ml ). these results indicate that pituicytes are not the major source of serum hmg1 levels and that macrophages may play a quantitatively more important role .
there is disclosed a pharmaceutical composition and method for treating sepsis , including septic shock and ards , comprising administering an effective amount of a hmg1 antagonist . there is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock , comprising measuring the serum concentration of hmg1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms . lastly , there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity , comprising administering an effective amount of hmg1 or a therapeutically active hmg1 fragment .